Literature DB >> 12203212

High expression levels of insulin-like growth factor-I receptor predict poor survival among women with clear-cell renal cell carcinomas.

Alexander S Parker1, John C Cheville, Carol A Janney, James R Cerhan.   

Abstract

Currently, tumor stage and grade remain the only widely accepted prognostic indicators of clear-cell renal cell carcinoma (CC-RCC). As such, there is a need to identify other prognostic markers because behavior of CC-RCC cannot always be determined by stage alone. Recent studies of human CC-RCC cell lines suggest that insulin-like growth factor-I receptor (IGF-IR) may have some prognostic value for patients with CC-RCC. Using a population-based cohort of 48 female patients with CC-RCC and long-term follow-up, we tested the hypothesis that the immunohistochemical detection of IGF-IR expression in CC-RCC is associated with poorer cancer-specific survival after adjustment for stage and age at diagnosis. Kaplan-Meier analysis suggested that patients with CC-RCC that exhibited greater than 50% IGF-IR expression experienced a significantly poorer cancer-specific survival compared with patients with CC-RCC that exhibited less than 50% IGF-IR expression. The difference in survival was apparent at 2 years and remained throughout follow-up. Based on a Cox proportional hazard model that adjusted for stage and age at diagnosis, patients with tumors that exhibited greater than 50% IGF-IR staining were 4 times more likely to die of CC-RCC compared with patients whose tumors exhibited less than 50% staining (HR = 4.2; 95% confidence interval [CI]; 1.1-17.1). A smoothing spline with 4 degrees of freedom supported the results from the categorical analysis. Evidence from this population-based pilot investigation is consistent with laboratory data suggesting that expression of IGF-IR may have some prognostic implication for patients presenting with CC-RCC; however, confirmation in a larger study is needed. Copyright 2002, Elsevier Science (USA). All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12203212     DOI: 10.1053/hupa.2002.126186

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  14 in total

1.  Mutational and immunohistochemical study of the PI3K/Akt pathway in papillary thyroid carcinoma in Greece.

Authors:  Elias Sozopoulos; Helen Litsiou; Gerassimos Voutsinas; Nikolaos Mitsiades; Nikolaos Anagnostakis; Thomais Tseva; Efstratios Patsouris; Sofia Tseleni-Balafouta
Journal:  Endocr Pathol       Date:  2010-06       Impact factor: 3.943

2.  HuR expression is a marker of poor prognosis in renal cell carcinoma.

Authors:  Hanna Ronkainen; Markku H Vaarala; Pasi Hirvikoski; Ari Ristimäki
Journal:  Tumour Biol       Date:  2010-12-16

3.  18FDG-PET predicts pharmacodynamic response to OSI-906, a dual IGF-1R/IR inhibitor, in preclinical mouse models of lung cancer.

Authors:  Eliot T McKinley; Joseph E Bugaj; Ping Zhao; Saffet Guleryuz; Christine Mantis; Prafulla C Gokhale; Robert Wild; H Charles Manning
Journal:  Clin Cancer Res       Date:  2011-01-21       Impact factor: 12.531

4.  Relevance of insulin-like growth factor 1 receptor gene expression as a prognostic factor in non-small-cell lung cancer.

Authors:  M Teresa Agulló-Ortuño; C Vanesa Díaz-García; Alba Agudo-López; Carlos Pérez; Ana Cortijo; Luis Paz-Ares; Fernando López-Ríos; Francisco Pozo; Javier de Castro; Hernán Cortés-Funes; José A López Martín
Journal:  J Cancer Res Clin Oncol       Date:  2014-08-01       Impact factor: 4.553

5.  MicroRNA-214 Reduces Insulin-like Growth Factor-1 (IGF-1) Receptor Expression and Downstream mTORC1 Signaling in Renal Carcinoma Cells.

Authors:  Falguni Das; Nirmalya Dey; Amit Bera; Balakuntalam S Kasinath; Nandini Ghosh-Choudhury; Goutam Ghosh Choudhury
Journal:  J Biol Chem       Date:  2016-05-13       Impact factor: 5.157

6.  Phase I Dose-Escalation Study of Linsitinib (OSI-906) and Erlotinib in Patients with Advanced Solid Tumors.

Authors:  Valentine M Macaulay; Mark R Middleton; S Gail Eckhardt; Charles M Rudin; Rosalyn A Juergens; Richard Gedrich; Sven Gogov; Sean McCarthy; Srinivasu Poondru; Andrew W Stephens; Shirish M Gadgeel
Journal:  Clin Cancer Res       Date:  2016-02-01       Impact factor: 12.531

7.  IGF-1 receptor is down-regulated by sunitinib induces MDM2-dependent ubiquitination.

Authors:  Hongchang Shen; Yan Fang; Wei Dong; Xueru Mu; Qi Liu; Jiajun Du
Journal:  FEBS Open Bio       Date:  2011-12-27       Impact factor: 2.693

8.  Molecular targeted therapy in advanced renal cell carcinoma: A review of its recent past and a glimpse into the near future.

Authors:  John S P Yuen
Journal:  Indian J Urol       Date:  2009 Oct-Dec

9.  Recent alcohol consumption and risk of incident ovarian carcinoma: a pooled analysis of 5,342 cases and 10,358 controls from the Ovarian Cancer Association Consortium.

Authors:  Linda E Kelemen; Elisa V Bandera; Kathryn L Terry; Mary Anne Rossing; Louise A Brinton; Jennifer A Doherty; Roberta B Ness; Susanne Krüger Kjaer; Jenny Chang-Claude; Martin Köbel; Galina Lurie; Pamela J Thompson; Michael E Carney; Kirsten Moysich; Robert Edwards; Clare Bunker; Allan Jensen; Estrid Høgdall; Daniel W Cramer; Allison F Vitonis; Sara H Olson; Melony King; Urmila Chandran; Jolanta Lissowska; Montserrat Garcia-Closas; Hannah Yang; Penelope M Webb; Joellen M Schildkraut; Marc T Goodman; Harvey A Risch
Journal:  BMC Cancer       Date:  2013-01-22       Impact factor: 4.430

10.  A twenty-first century cancer epidemic caused by obesity: the involvement of insulin, diabetes, and insulin-like growth factors.

Authors:  Rosalyne L Westley; Felicity E B May
Journal:  Int J Endocrinol       Date:  2013-07-31       Impact factor: 3.257

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.